Document is current
Any future updates will be listed below
-
Authors
Hawman, David W. https://orcid.org/0000-0001-8233-8176
Tipih, Thomas https://orcid.org/0000-0003-3845-1942
Hodge, Eddie https://orcid.org/0000-0003-1606-5821
Stone, E. Taylor
Warner, Nikole https://orcid.org/0000-0002-2307-5529
McCarthy, Natalie
Granger, Brian
Meade-White, Kimberly
Leventhal, Shanna
Hatzakis, Kiara
Park, Stephanie https://orcid.org/0009-0008-8954-9265
Gaffney, Karen
Rosenke, Kyle https://orcid.org/0000-0001-8101-4348
Erasmus, Jesse H. https://orcid.org/0000-0003-1612-2697
Feldmann, Heinz https://orcid.org/0000-0001-9448-8227
- License Information
-
More Information
Article History
Received: 18 September 2024
Accepted: 17 December 2024
First Online: 14 January 2025
Competing interests
: J.H.E., E.T.S., N.W., S.P., K.H., E.H., and K.G. have an equity interest in HDT Bio. J.H.E. is an inventor on patents (US Patent nos. 11,458,209; 11,433,142; 11,752,218; 11,648,321; and 11,654,200) and patent applications (PCT/US22/76787, PCT/US23/60225, and PCT/US2024/010326) pertaining to the LION formulation and repRNA compositions described in the studies. Funders had no role in study design, data interpretation or decision to publish. The remaining authors declare no competing interests.
